materiaux

A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers. Led by Co-director Ralph Weichselbaum, investigator Wenbin Lin and postdoctoral researcher Kaiting Yang at the Ludwig Center at Chicago, the study describes the synthesis, mechanism of action and preclinical assessment of the nanoparticle, which is loaded with a drug that activates a protein central to the efficient induction of anti-cancer immunity.

In a study published in Nature (« Functional CeOx nanoglues for robust atomically dispersed catalysts »), a research team led by Prof. ZENG Jie from the University of Science and Technology of China (USTC) of the Chinese Academy of Sciences and international collaborators developed a novel “nanoglue” strategy to stabilize atomically dispersed metal catalysts.